

#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Walti 1



Section 1. Identifying Inform	ation		
Given Name (First Name)  Carla	2. Surname (Last Name) Walti		3. Date 03-March-2021
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author	or's Name
5. Manuscript Title Antibodies to vaccine-preventable infecti	ons after CAR-T-cell thera	py for B-cell malignar	ncies
6. Manuscript Identifying Number (if you kn 146743-INS-CMED-TR-2	ow it)		
		_	
Section 2. The Work Under Co	onsideration for Public	ation	
any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by press	st? Yes No No ormation below. If you have sing the "X" button.	a monitoring board, stu	ty press the "ADD" button to add a row.
Name of Institution/Company	Giant'	n-Financial other?	Comments
Swiss National Science Foundation			P2BSP3 188162 Early Postdoc. Mobility
			ADD
Section 3. Relevant financial	activities outside the s	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as descri clicking the "Add +" box. You should repare there any relevant conflicts of interest	in the table to indicate who bed in the instructions. Us port relationships that were	ether you have finand e one line for each ei	ntity; add as many lines as you need by
Section 4. Intellectual Propert	y Patents & Copyrigl	nts	
Do you have any patents, whether plant	ned, pending or issued, br	oadly relevant to the	work? ☐ Yes   ✓ No

Walti 2



Ocetica E	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
Dr. Walti reports	grants from Swiss National Science Foundation, during the conduct of the study; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Walti 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Krantz 1





Section 1.	Identifying Inform	nation		
1. Given Name (Fi Elizabeth	rst Name)	2. Surname (Last Name) Krantz		3. Date 03-March-2021
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Nam Joshua A. Hill	ne
5. Manuscript Title Antibodies to vac		ions after CAR-T-cell thera	py for B-cell malignancies	
6. Manuscript Ider 146743-INS-CN	ntifying Number (if you kn MED-TR-2	now it)		
			_	
Section 2.	The Work Under C	onsideration for Publica	ation	
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?				
Are there any rei	evant conflicts of intere	est?		ADD
Section 3.	Relevant financial	activities outside the s	submitted work.	
of compensation clicking the "Add	the appropriate boxes ) with entities as descri	in the table to indicate who bed in the instructions. Us port relationships that were	ether you have financial rela	tionships (regardless of amount dd as many lines as you need by onths prior to publication.
Continu	l			
Section 4.	Intellectual Propert	y Patents & Copyrigh	nts	
Do you have any	patents, whether plan	ned, pending or issued, bro	oadly relevant to the work?	☐ Yes 🗸 No

Krantz 2



Cootion F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
E. Krantz has not	hing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Krantz 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Maalouf 1



Section 1. Identifying Inform	nation			
Given Name (First Name)  Joyce	Surname (Last Name)     Maalouf	3. Date 04-March-2021		
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Joshua A. Hill		
5. Manuscript Title Antibodies to vaccine-preventable infection	ions after CAR-T-cell thera	py for B-cell malignancies		
6. Manuscript Identifying Number (if you kn 146743-INS-CMED-TR-2	ow it)			
Section 2. The Work Under Co	onsideration for Publica	ation		
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No				
		ADD		
Section 3. Relevant financial		1 10 1		
Relevant financial	activities outside the s	submitted work.		
of compensation) with entities as descri	bed in the instructions. Us port relationships that were	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.		
		ADD		
Section 4. Intellectual Propert	y Patents & Copyrigh	nts		
Do you have any patents, whether plant	ned, pending or issued, bro	oadly relevant to the work? Yes No		

Maalouf 2



Continu F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of incing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
J. Maalouf has no	othing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Maalouf 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Boonyaratanakornkit 1



Section 1. Identifying Inform	ation		
Given Name (First Name) Jim	Surname (Last Name)     Boonyaratanakornkit		3. Date 04-March-2021
4. Are you the corresponding author?	☐ Yes   ✓ No	Corresponding Author Joshua A. Hill	r's Name
5. Manuscript Title Antibodies to vaccine-preventable infection	ons after CAR-T-cell thera	py for B-cell malignan	cies
6. Manuscript Identifying Number (if you know 146743-INS-CMED-TR-2	ow it)		
		_	
Section 2. The Work Under Co	onsideration for Public	ation	
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interest yes, please fill out the appropriate info Excess rows can be removed by press	but not limited to grants, dat st?  Yes  No rmation below. If you hav	a monitoring board, stud	dy design, manuscript preparation,
Name of Institution/Company	Grant? Personal Nor	n-Financial other?	Comments
American Society for Transplantation and Cellular Therapy	<b>✓</b>		×
			ADD
Section 3. Relevant financial a	activities outside the s	submitted work.	
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interesting the statement of th	oed in the instructions. Us ort relationships that were	e one line for each en	tity; add as many lines as you need by
Section 4. Intellectual Property	y Patents & CopyrigI	nts	
Do you have any patents, whether plann			vork? ☐ Yes  ✔ No

Boonyaratanakornkit 2



Continu F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
Dr. Boonyaratan conduct of the s	akornkit reports grants from American Society for Transplantation and Cellular Therapy, during the tudy;.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Boonyaratanakornkit 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Keane-Candib 1





Section 1.	Identifying Inform	nation		
Given Name (Fill Jacob	rst Name)	Surname (Last Name) Keane-Candib		Date -March-2021
4. Are you the cor	responding author?	☐ Yes 🗸 No	Corresponding Author's Name Joshua A. Hill	
5. Manuscript Title Antibodies to vac		ions after CAR-T-cell thera	py for B-cell malignancies	
6. Manuscript Ider 146743-INS-CN	ntifying Number (if you kn MED-TR-2	now it)		
			-	
Section 2.	The Work Under Co	onsideration for Publica	ation	
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No				
Are there any rei	evant connicts of intere	est?		ADD
Section 3.	Relevant financial	activities outside the s	ubmitted work.	
of compensation clicking the "Add	) with entities as descri	bed in the instructions. Us port relationships that were	ether you have financial relatior e one line for each entity; add a e present during the 36 month	as many lines as you need by
Section 4.	Intellectual Propert	y Patents & Copyrigl	nts	
Do you have any	v patents, whether plan	ned, pending or issued, br	oadly relevant to the work?	Yes ✓ No

Keane-Candib 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
J. Keane-Candib	has nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Keane-Candib 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Joncas-Schronce 1





Section 1. Identifying Inform	nation	
Given Name (First Name)  Laurel	Surname (Last Name)  Joncas-Schronce	3. Date 04-March-2021
4. Are you the corresponding author?	☐ Yes 🗸 No	Corresponding Author's Name Joshua A. Hill
5. Manuscript Title Antibodies to vaccine-preventable infect	ions after CAR-T-cell thera	py for B-cell malignancies
6. Manuscript Identifying Number (if you kr 146743-INS-CMED-TR-2	now it)	
Section 2. The Work Under C	onsideration for Public	ation
	but not limited to grants, dat	a third party (government, commercial, private foundation, etc.) for a monitoring board, study design, manuscript preparation,
·		ADD
Section 3. Polovant financial		
Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that were	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.
		ADD
Section 4. Intellectual Propert	ty Patents & Copyrigl	nts
intenectual i Topen	iy i atents a copyrigi	<u> </u>
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes No

Joncas-Schronce 2



Cootion F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
L. Joncas-Schror	nce has nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Joncas-Schronce 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Stevens-Ayers 1





Section 1. Identifying Inform	nation	
Given Name (First Name)  Terry	Surname (Last Name)     Stevens-Ayers	3. Date 02-March-2021
4. Are you the corresponding author?	☐ Yes   ✓ No	Corresponding Author's Name Joshua A. Hill
5. Manuscript Title Antibodies to vaccine-preventable infect	ions after CAR-T-cell thera	py for B-cell malignancies
6. Manuscript Identifying Number (if you kr 146743-INS-CMED-TR-2	now it)	
		_
Section 2. The Work Under C	onsideration for Public	ation
	but not limited to grants, dat	a third party (government, commercial, private foundation, etc.) for a monitoring board, study design, manuscript preparation,
,		ADD
Section 3. Polovant financial		
Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that were	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.
		ADD
Section 4. Intellectual Proper		
Intellectual Proper	ty Patents & Copyrig	hts
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes No

Stevens-Ayers 2



Oradian F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
Dr. Stevens-Ayer	s has nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Stevens-Ayers 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Dasgupta 1





Section 1. Identifying Inform	nation	
Given Name (First Name) Sayan	Surname (Last Name)     Dasgupta	3. Date 02-March-2021
4. Are you the corresponding author?	☐ Yes 🗸 No	Corresponding Author's Name Joshua A. Hill
5. Manuscript Title Antibodies to vaccine-preventable infect	ions after CAR-T-cell thera	py for B-cell malignancies
6. Manuscript Identifying Number (if you kr 146743-INS-CMED-TR-2	now it)	
Section 2. The Work Under C	onsideration for Public	ation
	but not limited to grants, dat	a third party (government, commercial, private foundation, etc.) for a monitoring board, study design, manuscript preparation,
·		ADD
Section 3. Polovant financial		
Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that were	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.
		ADD
Section 4. Intellectual Property	ty Patents & Copyrig	nts
Do you have any patents, whether plan		

Dasgupta 2



Section 5.	
occion 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
Dr. Dasgupta has	s nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Dasgupta 3

#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Taylor 1



Section 1. Identifying Inform	mation		
Given Name (First Name)  Justin	Surname (Last Name)     Taylor	3. Date 04-March-2021	
4. Are you the corresponding author?	☐ Yes   ✓ No	Corresponding Author's Name Joshua A. Hill	
5. Manuscript Title Antibodies to vaccine-preventable infec	tions after CAR-T-cell ther	apy for B-cell malignancies	
6. Manuscript Identifying Number (if you k 146743-INS-CMED-TR-2	now it)		
On the second			
Section 2. The Work Under C	onsideration for Public	cation	
	g but not limited to grants, da	n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,  AD	
Section 3. Relevant financia	l activities outside the	submitted work.	
of compensation) with entities as describing the "Add +" box. You should re Are there any relevant conflicts of inter-	ribed in the instructions. Usport relationships that werest? Yes No	hether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.	
If yes, please fill out the appropriate int	formation below.		
Name of Entity	Grant -	on-Financial Other? Comments	
Vir Biotechnology	<b>✓</b>	×	
		ADI	D
Section 4. Intellectual Proper	ty Patents & Copyrig	hts	
Do you have any patents, whether plar	nned, pending or issued, b	proadly relevant to the work? Yes V	

Taylor 2



Ocetion 5	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
Dr. Taylor reports	s a Sponsored Research Agreement from Vir Biotechnology , outside the submitted work; .

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Taylor 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Hirayama 1



Section 1. Identifying Inform	mation	
1. Given Name (First Name) Alexandre	Surname (Last Name)     Hirayama	3. Date 04-March-2021
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Joshua A. Hill
5. Manuscript Title Antibodies to vaccine-preventable infec	ctions after CAR-T-cell there	apy for B-cell malignancies
6. Manuscript Identifying Number (if you k 146743-INS-CMED-TR-2	now it)	_
Section 2. The Work Under C	Consideration for Public	ation
Did you or your institution at any time rece	eive payment or services from g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financia	l activities outside the	submitted work.
of compensation) with entities as desc	ribed in the instructions. Useport relationships that werest?   Yes No	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.
Name of Entity	Grant? Personal No	n-Financial Other? Comments
Celgene, a Bristol Myers Squibb company		Lecture × ADD
Section 4. Intellectual Proper	rty Patents & Copyrig	hts
Do you have any patents, whether plan	nned, pending or issued, b	roadly relevant to the work? Yes Vo

Hirayama 2



On the F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Disc	closure Statement
Dr. Hirayama rep	orts personal fees from Celgene, a Bristol Myers Squibb company, outside the submitted work; .

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Hirayama 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Bar 1





Section 1.	Identifying Inform	nation		
1. Given Name (Fir Merav	rst Name)	Surname (Last Name) Bar	3. D 03-N	ate March-2021
4. Are you the corr	responding author?	☐ Yes 🗸 No	Corresponding Author's Name Joshua A. Hill	
5. Manuscript Title Antibodies to vac		ions after CAR-T-cell thera	by for B-cell malignancies	
6. Manuscript Ider 146743-INS-CN	ntifying Number (if you kn MED-TR-2	now it)		
			-	
Section 2.	The Work Under C	onsideration for Publica	ation	
any aspect of the s statistical analysis	submitted work (including s, etc.)?	but not limited to grants, date	a third party (government, commerc a monitoring board, study design, m	
Are there any rel	evant conflicts of intere	est?		ADD
Section 3.	Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest?  Yes  No				
Cootion 4	ı			
Section 4.	Intellectual Propert	ty Patents & Copyrigh	its	
Do you have any	patents, whether plan	ned, pending or issued, bro	oadly relevant to the work?	Yes 🗸 No

Bar 2



On all and E	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Bar has nothing	

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Bar 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Gardner 1





Section 1. Identifying Informa	ntion			
Given Name (First Name)  Rebecca	2. Surname (Last Name) Gardner		3. Date 04-March-2021	
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Joshua A. Hill	s Name	
5. Manuscript Title Antibodies to vaccine-preventable infectio	ns after CAR-T-cell there	apy for B-cell malignancie	es	
6. Manuscript Identifying Number (if you know 146743-INS-CMED-TR-2	w it)			
Section 2. The Work Under Cor	nsideration for Public	ation		
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including be statistical analysis, etc.)?  Are there any relevant conflicts of interes	out not limited to grants, da			c.) for
				ADD
Section 3. Relevant financial a	ctivities outside the	submitted work.		
Place a check in the appropriate boxes in of compensation) with entities as describ clicking the "Add +" box. You should repo	ed in the instructions. Use ort relationships that wer	se one line for each entity	y; add as many lines as you nee	
Are there any relevant conflicts of interes				
If yes, please fill out the appropriate infor	mation below.			
Name of Entity	Grant? Personal No	n-Financial Other?	Comments	
Pfizer				×
Janssen				×
Novartis				×
BMS		st.	eering committee	× ADD

Gardner 2



Section 4. Intellectual F	Property Patents &	& Copyrights			
Do you have any patents, wheth If yes, please fill out the approp Excess rows can be removed by	riate information below	v. If you have more tha		Yes No the "ADD" button to add a row	V.
Patent?	Pending? Issued?	Licensed? Royalties?	Licensee?	Comments	
Patent		<b>✓</b>		;	K
				A	DD
Continu 5					
Section 5. Relationship	os not covered abov	ve			
Are there other relationships or potentially influencing, what yo		•	influenced, or tha	at give the appearance of	
Yes, the following relationsh	•		. ,		
✓ No other relationships/conditions/circumstances that present a potential conflict of interest					
At the time of manuscript accep On occasion, journals may ask					ts.
Section 6. Disclosure S	statement				
Based on the above disclosures below.	s, this form will automa	tically generate a discl	osure statement,	which will appear in the box	
Generate Disclosure Statem	ent				
Dr. Gardner has served on an a to BMS	dvisory board for Norva	atis, serves on a steerir	ng committee for B	MS and has a patent licensed	

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Gardner 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Cowan 1



Section 1.	Identifying Inform	ation				
1. Given Name (Fi Andrew	rst Name)	Surname (Last Nat Cowan	me)		3. Date 10-March-2021	
4. Are you the cor	responding author?	☐ Yes ✓ No	Correspond Joshua A. I	ling Author's Nar Hill	ne	
5. Manuscript Title Antibodies to vac	e ccine-preventable infecti	ons after CAR-T-cell	therapy for B-cell	malignancies		
6. Manuscript Ider 146743-INS-CM	ntifying Number (if you know MED-TR-2	ow it)				
Section 2.	The Work Under Co	onsideration for P	ublication			
any aspect of the s statistical analysis	submitted work (including	but not limited to gran			nmercial, private foundation, eto gn, manuscript preparation,	c.) for
7 no more any ron		on				ADD
Section 3.	Relevant financial	activities outside	the submitted v	work.		
of compensation clicking the "Add Are there any rel	) with entities as descri	bed in the instruction ort relationships that st?  Yes	s. Use one line for	r each entity; a	ationships (regardless of amodd as many lines as you nee onths prior to publication.	
Name of Entity		Grant? Personal Fees?	Non-Financial C	Other? Comm	ents	
Janssen		<b>✓</b>				×
Sanofi						×
Bristol Myers Squibb						×
Harpoon						×
Nektar						×
Janssen				Consu		×
Cellectar				Consu		×
Sanofi				Consu	ulting	×
		1				

Cowan 2



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments	
Abbvie			Consulting	×
Section 4. Intellectual Property	/ Patents & Cop	yrights		ADD
Do you have any patents, whether plann	ed, pending or issue	d, broadly releva	nt to the work? Yes	<b>✓</b> No
Section 5. Relationships not of	covered above			
Are there other relationships or activities potentially influencing, what you wrote			nfluenced, or that give the a	ppearance of
Yes, the following relationships/cond	litions/circumstances	are present (exp	olain below):	
No other relationships/conditions/circ	cumstances that pres	sent a potential c	conflict of interest	
At the time of manuscript acceptance, journals may ask authors to				isclosure statements.
Section 6. Disclosure Statemer	nt			
Based on the above disclosures, this formula below.		generate a disclo	sure statement, which will ap	opear in the box
Generate Disclosure Statement				
Dr. Cowan reports grants from Janssen, from Nektar, personal fees from Janssen outside the submitted work; .				

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Cowan 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Informs		
Identifying Information	ation	
Given Name (First Name)  Damian	2. Surname (Last Na Green	ame) 3. Date 04-March-2021
4. Are you the corresponding author?	☐ Yes 🗸 No	Corresponding Author's Name Joshua A. Hill
5. Manuscript Title Antibodies to vaccine-preventable infection	ons after CAR-T-cel	Il therapy for B-cell malignancies
6. Manuscript Identifying Number (if you know 146743-INS-CMED-TR-2	ow it)	
Section 2. The Work Under Co	nsideration for P	ublication
any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grar	es from a third party (government, commercial, private foundation, etc.) for nts, data monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of interes If yes, please fill out the appropriate info Excess rows can be removed by pressi	rmation below. If yo	No ou have more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Persona	Non-Financial Support? Comments
National Institutes of Health National Cancer Institute (NIH/NCI)	<b>✓</b>	P01CA018029 ×
Juno Therapeutics		ADD
Section 3. Relevant financial a	activities outside	e the submitted work.
of compensation) with entities as describ clicking the "Add +" box. You should rep	oed in the instruction ort relationships tha	ate whether you have financial relationships (regardless of amount ons. Use one line for each entity; add as many lines as you need by at were <b>present during the 36 months prior to publication</b> .
Are there any relevant conflicts of interes		No
If yes, please fill out the appropriate info	rmation below.	
Name of Entity	Grant Persona	Non-Financial Other? Comments Support?
Juno Therapeutics	<b>/</b>	×
Seattle Genetics		×



Name of Entity	Grant?	Personal	Non-Financial	Other?	Comments	
Name of Littly	- Grant	Fees?	Support?	Otner •	Comments	
Cellectar Biosciences						×
Jansen Pharmaceutical						×
Celgene Corporation						×
Legend Biotech		<b>7</b>				×
Logona Biotosii		<b>✓</b>				×
						ADD
Section 4. Intellectual Prope	ertv Pater	nts & Copy	riahts			
Do you have any patents, whether pla If yes, please fill out the appropriate in Excess rows can be removed by pre	nformation be	elow. If you	•			a row.
Patent? Pend	ding? Issue	d? Licensed	Royalties?	License	? Comments	
Juno Therapeutics [			<b>√</b>			×
						ADD
Section 5. Relationships no	ot covered	above				
Are there other relationships or activity potentially influencing, what you wro	ties that read	ers could pe		influenced	d, or that give the appearance of	
Yes, the following relationships/co	onditions/circ	umstances	are present (ex	plain belov	w):	
✓ No other relationships/conditions/					•	
At the time of manuscript acceptance On occasion, journals may ask author	•				• •	nents.



### Section 6.

### Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

### **Generate Disclosure Statement**

Dr. Green reports grants from National Institutes of Health National Cancer Institute (NIH/NCI), grants from Juno Therapeutics, during the conduct of the study; grants and personal fees from Juno Therapeutics, grants and personal fees from Seattle Genetics, personal fees from GlaxoSmithKline, grants from Cellectar Biosciences, grants and personal fees from Jansen Pharmaceutical, personal fees from Celgene Corporation, personal fees from Legend Biotech, outside the submitted work; In addition, Dr. Green has a patent Juno Therapeutics with royalties paid.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Boeckh 1



Identifying Information

Section 1.

# **ICMJE** Form for Disclosure of Potential Conflicts of Interest

Given Name (First Name)     Michael	2. Surname Boeckh	e (Last Name)			3. Date 03-March-2021
4. Are you the corresponding author?	Yes	<b>✓</b> No	Correspor Joshua A	nding Author's I . Hill	Name
5. Manuscript Title Antibodies to vaccine-preventable infe	ctions after CA	AR-T-cell thera	py for B-ce	I malignancie	S
6. Manuscript Identifying Number (if you In 146743-INS-CMED-TR-2	know it)		_		
Section 2. The Work Under (	Consideratio	on for Public	ation		
Did you or your institution at any time recany aspect of the submitted work (includir statistical analysis, etc.)?	ng but not limite	ed to grants, dat			
Are there any relevant conflicts of inte	rest? Ye	es 🔽 No			AD
Section 3. Relevant financia	al activities	outside the s	submitted	work.	
Place a check in the appropriate boxe of compensation) with entities as described the "Add +" box. You should read the there any relevant conflicts of interesting the second sec	cribed in the in eport relations	structions. Us ships that were	e one line f	or each entity	; add as many lines as you need by
If yes, please fill out the appropriate in	٠				
Name of Entity	Grant?	Personal Non	-Financial	Other? Cor	nments
Merck	<b>✓</b>	<b>✓</b>			×
Gilead		$\checkmark$			×
GlaxoSmithKline					×
Janssen					×
Regeneron					×
Allovir		<b>1</b>			×
Moderna		<b>✓</b>			×
Helocyte		<b>✓</b>			×
Boeckh		✓			



ADD Section 4. Intellectual Property -- Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Section 5. Relationships not covered above Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below):  $lap{No other relationships/conditions/circumstances that present a potential conflict of interest$ At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. Section 6. Disclosure Statement Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. **Generate Disclosure Statement** Dr. Boeckh reports grants and personal fees from Merck, grants and personal fees from Gilead, grants from GlaxoSmithKline, grants and personal fees from Janssen, personal fees from Regeneron, personal fees from Allovir, personal fees from Moderna, personal fees from Helocyte, outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Boeckh 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Maloney 1



Section 1. Identifying Information	ation			
Given Name (First Name)  David	Surname (Last Name)     Maloney		3. Date 04-March-2021	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author	or's Name	
5. Manuscript Title Antibodies to vaccine-preventable infection	ons after CAR-T-cell thera	py for B-cell malignar	ncies	
6. Manuscript Identifying Number (if you kno	ow it)			
Section 2. The Work Under Co	nsideration for Public	ation		
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)?				:.) for
Are there any relevant conflicts of interes	st? ✓ Yes No			
If yes, please fill out the appropriate info		e more than one enti	ty press the "ADD" button to add a	row.
Excess rows can be removed by press				
Name of Institution/Company	Grant? Personal Nor	upport?	Comments	
Juno Therapeutics			Grant paid to institution in support of clinical trial research	×
				ADD
Section 3. Relevant financial of				
Relevant financial a	activities outside the s	submitted work.		
Place a check in the appropriate boxes i of compensation) with entities as describ clicking the "Add +" box. You should rep	ed in the instructions. Us	e one line for each er	ntity; add as many lines as you need	
Are there any relevant conflicts of interes	st? Yes No			
If yes, please fill out the appropriate info	rmation below.			
Name of Entity	Grant? Personal Non	Financial Other?	Comments	
A2 Biotherapeutics			Honorarium paid as a member of the Scientific Steering Committee; stock options	×

Maloney 2



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Bioline Rx		<b>✓</b>			Honorarium paid as member of a protocol specific data monitoring committee	×
Celgene	<b>✓</b>	<b>✓</b>			Grant paid to institution in support of clinical trial research; Honorarium for participation in an ad hoc advisory board meeting.	×
Kite Pharma	<b>✓</b>	<b>✓</b>			Grant paid to institution in support of clinical trial research; Honorarium for participation in an ad hoc advisory board meeting.	×
Gilead		1			Honorarium for participation in an ad hoc advisory board meeting.	×
Novartis		<b>✓</b>			Honorarium for participation in an ad hoc advisory board meeting.	×
Pharmacyclics		<b>✓</b>			Honorarium for participation in an ad hoc advisory board meeting.	×
Eureka		<b>✓</b>			Honorarium for participation in an ad hoc advisory board meeting.	×
Genentech		1			Honorarium for participation in an ad hoc advisory board meeting.	×
BMS		1			Honorarium for participation in an ad hoc advisory board meeting.	×
Janssen		1			Honorarium for participation in an ad hoc advisory board meeting.	×
Legend Biotech		1			Honorarium for participation in an ad hoc advisory board meeting.	×
MorphoSys		1			Honorarium for participation in an ad hoc advisory board meeting.	×
Amgen		1			Honorarium for participation in an ad hoc advisory board meeting.	×
Juno		1			Honorarium for participation in an ad hoc advisory board meeting.	×
						ADD
Section 4. Intellectual Property	/ Pate	nts & Co	nyriahts			
Do you have any patents, whether plann If yes, please fill out the appropriate inform	ed, pendi	ng or issue	d, broadly releva			row.

Maloney 3

Excess rows can be removed by pressing the "X" button.



Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments	
Juno Therapeutics	<b>✓</b>						X
							ADD

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

# Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

#### **Generate Disclosure Statement**

Dr. Maloney reports grants from Juno Therapeutics, during the conduct of the study; personal fees from A2 Biotherapeutics, Bioline Rx, Juno Therapeutics, Genentech, Amgen, BMS, Gilead, Morphosys, Novartis, Legend Biotech, Janssen, Pharmacyclics and Eureka outside of the submitted work; Research grant paid to institution and personal fees from Celgene, and Kite Pharma. In addition, Dr. Maloney has patents pending with Juno Therapeutics and stock options with A2 Biotherapeutics.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Maloney 4



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Informs						
Identifying Information	ation					
Given Name (First Name)     Cameron	2. Surnar Turtle	me (Last Name	e)		3. Date 04-March-2021	
4. Are you the corresponding author?	Yes	<b>✓</b> No	Correspon Joshua A.	ding Autho Hill	r's Name	
5. Manuscript Title Antibodies to vaccine-preventable infection	ons after (	CAR-T-cell th	nerapy for B-cel	l malignan	cies	
6. Manuscript Identifying Number (if you kno	w it)					
Section 2. The Work Under Co	nsiderat	ion for Pub	olication			
Did you or your institution <b>at any time</b> receiv any aspect of the submitted work (including l statistical analysis, etc.)?						c.) for
Are there any relevant conflicts of interes		Yes N				
If yes, please fill out the appropriate info Excess rows can be removed by pressi			have more thar	one entit	y press the "ADD" button to add a	row.
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support	Other?	Comments	
Juno Therapeutics/BMS	1					×
National Institutes of Health National Cancer Institute (NIH/NCI)	<b>4</b>					×
						ADD
Section 3. Relevant financial of	otivitio	a autoida ti	a a a ub mittad	work		
Relevant financial a	ctivities	s outside ti	ie Submittea	work.		
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report the state of the s	ed in the	instructions.	. Use one line fo	or each en	tity; add as many lines as you need	
Are there any relevant conflicts of interes	it? 🔽 `	Yes N	0			
If yes, please fill out the appropriate info	mation b	elow.				
Name of Entity	Grant?	Personal Fees?	Non-Financial Support <mark>?</mark>	Other?	Comments	
Nektar Therapeutics	1	<b>✓</b>	<b>/</b>		Drug supply for lab research	×
Astra Zeneca	<u> </u>	<u> </u>				×



Name of Entity	Gr	ant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Precision Biosciences			$\Box$		7	Stock options; Advisory board member	×
Eureka Therapeutics					<u></u> ✓	Stock options; Advisory board member	×
Caribou Biosciences					<u> </u>	Stock options; Advisory board member	×
T-CURX					<b>\</b>	Advisory board member (unpaid)	×
Myeloid Therapeutics			<u> </u>			Stock options; Advisory board member	×
ArsenalBio			<u> </u>		<b>✓</b>	Stock options; Advisory board member	×
Century Therapeutics			<u> </u>		<u> </u>	Advisory board member	×
Allogene			<u> </u>				×
PACT Pharma			<u> </u>				×
Astra Zeneca			<u> </u>				×
Juno Therapeutics/BMS		7					×
AsherBio			<u></u>				×
Kite/Gilead			<b>_</b>				×
Novartis			<b>7</b>				×
Humanigen			<b>✓</b>				×
Aptevo			<b>✓</b>				×
							ADD
Section 4. Intellectual Pr	operty	Paten	ts & Cop	yrights			
Do you have any patents, whethe If yes, please fill out the appropria Excess rows can be removed by	ate informa	tion be	elow. If you	•		work? ✓ Yes ☐ No y press the "ADD" button to add a r	ow.
Patent?	Pending?	Issue	d? License	ed? Royalties?	License	? Comments	
Drug effluxing T cells		<b>√</b>	<b>_</b>		Juno/BMS	S Unrelated	×
CD19 CAR-T cells for NHL, CLL, ALL	4				Juno/BMS	Related to CAR-T cell therapy; unrelated to infection/this paper; in licensing discussion	×

Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments	
Cytokines in CAR-T cell therapy	<b>✓</b>				Juno/BMS	Related to CAR-T cell therapy; unrelated to infection/this paper; in licensing discussion	×
							<b>ADD</b>

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

# Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

#### **Generate Disclosure Statement**

Dr. Turtle reports grants from Juno Therapeutics/BMS, grants from National Institutes of Health National Cancer Institute (NIH/NCI), during the conduct of the study; grants, personal fees and non-financial support from Nektar Therapeutics, grants and personal fees from Astra Zeneca, grants from TCR2 Therapeutics, personal fees and other from Precision Biosciences, other from Eureka Therapeutics, personal fees and other from Caribou Biosciences, other from T-CURX, personal fees and other from Myeloid Therapeutics, personal fees and other from ArsenalBio, personal fees and other from Century Therapeutics, personal fees from Allogene, personal fees from PACT Pharma, personal fees from Astra Zeneca, grants from Juno Therapeutics/BMS, personal fees from AsherBio, personal fees from Kite/Gilead, personal fees from Novartis, personal fees from Humanigen, personal fees from Aptevo, outside the submitted work; In addition, Dr. Turtle has a patent Drug effluxing T cells with royalties paid to Juno/BMS, a patent CD19 CAR-T cells for NHL, CLL, ALL pending to Juno/BMS, and a patent Cytokines in CAR-T cell therapy pending to Juno/BMS.

#### Evaluation and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Hill 1



Section 1						
Section 1. Identifying Information	ition					
Given Name (First Name)  Joshua	2. Surnan Hill	ne (Last Nar	me)		3. Date 03-March-2021	
4. Are you the corresponding author?	✓ Yes	No				
5. Manuscript Title Antibodies to vaccine-preventable infection	ns after (	CAR-T-cell	therapy for B-c	ell malignand	sies	
6. Manuscript Identifying Number (if you kno 146743-INS-CMED-TR-2	w it)					
Section 2. The Work Under Co	nsiderat	ion for Pi	ublication			
Did you or your institution at any time received any aspect of the submitted work (including be statistical analysis, etc.)?	e payment	or services	s from a third part			
Are there any relevant conflicts of interes	t? 🚺	res 🗌	No			
If yes, please fill out the appropriate infor Excess rows can be removed by pressi			u have more tha	an one entity	press the "ADD" button to a	dd a row.
Name of Institution/Company	Grant?		Non-Financia Support?	Other?	Comments	
National Institutes of Health National Cancer Institute (NIH/NCI)	1					×
NIH/NCI Cancer Center Support Grants	<b>✓</b>					×
						ADD
Ocation 0						
Section 3. Relevant financial a	ctivities	outside	the submitte	d work.		
Place a check in the appropriate boxes in of compensation) with entities as describ clicking the "Add +" box. You should report	ed in the	instruction	ıs. Use one line	for each ent	ity; add as many lines as you	ı need by
Are there any relevant conflicts of interes			No			
If yes, please fill out the appropriate infor	mation be	∌low.				
Name of Entity	Grant?	Personal Fees?	Non-Financia	Other?	Comments	
Allogene Therapeutics		1				×
CRISPR Therapeutics		1				×

Hill 2



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments	
Gilead Sciences	<b>/</b>			×
				ADD
Section 4. Intellectual Property	· Patents & Copy	yrights		
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo				
Section 5. Relationships not c	overed above			
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?				
Yes, the following relationships/conditions/circumstances are present (explain below):				
✓ No other relationships/conditions/circumstances that present a potential conflict of interest				
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.				
Section 6. Disclosure Statemer				
Disclosure Statemen				
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.				
Generate Disclosure Statement				
Dr. Hill reports grants from National Institutes of Health National Cancer Institute (NIH/NCI), grants from NIH/NCI Cancer Center Support Grants, during the conduct of the study; personal fees from Allogene Therapeutics, personal fees from CRISPR Therapeutics, grants and personal fees from Gilead Sciences, outside the submitted work;.				

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Hill 3